Avoro Capital Advisors LLC Makes New Investment in Septerna, Inc. (NASDAQ:SEPN)

Avoro Capital Advisors LLC purchased a new stake in shares of Septerna, Inc. (NASDAQ:SEPN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,110,000 shares of the company’s stock, valued at approximately $25,419,000. Avoro Capital Advisors LLC owned about 2.50% of Septerna at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Tower Research Capital LLC TRC acquired a new position in shares of Septerna during the fourth quarter valued at $25,000. TRV GP V LLC acquired a new position in Septerna during the 4th quarter valued at about $142,337,000. TRV GP VI LLC bought a new position in shares of Septerna in the 4th quarter valued at about $72,191,000. MetLife Investment Management LLC bought a new position in shares of Septerna in the 4th quarter valued at about $265,000. Finally, Walleye Capital LLC acquired a new stake in shares of Septerna during the 4th quarter worth approximately $463,000.

Insider Transactions at Septerna

In other news, CFO Gil M. Labrucherie bought 10,500 shares of the stock in a transaction on Wednesday, February 19th. The stock was acquired at an average price of $5.51 per share, with a total value of $57,855.00. Following the acquisition, the chief financial officer now directly owns 10,500 shares in the company, valued at approximately $57,855. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan Ezekowitz purchased 41,355 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were purchased at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the purchase, the director now directly owns 104,101 shares of the company’s stock, valued at approximately $624,606. This represents a 65.91 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 74,346 shares of company stock worth $439,670.

Septerna Stock Down 1.5 %

Shares of Septerna stock opened at $5.90 on Monday. The business has a 50-day simple moving average of $6.45. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99.

Septerna (NASDAQ:SEPN) last posted its earnings results on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. The company had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.13 million. As a group, equities research analysts expect that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on SEPN. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th. Wells Fargo & Company decreased their price objective on Septerna from $14.00 to $11.00 and set an “equal weight” rating for the company in a research note on Friday, March 28th.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.